Want to see INKT full AI Analyst Report?
INKT Stock Chart & Stats
$14.21
-$0.11(-11.96%)
At close: 4:00 PM EST
$14.21
-$0.11(-11.96%)
Day’s Range― - ―
52-Week Range$8.48 - $30.30
Previous CloseN/A
Volume98.55K
Average Volume (3M)39.56K
Market Cap
$53.85M
Enterprise Value$41.00
Total Cash (Recent Filing)$9.53M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Aug 12, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.83
Shares Outstanding4,981,899
10 Day Avg. Volume31,712
30 Day Avg. Volume39,559
Financial Highlights & Ratios
PEG Ratio-3.68
Price to Book (P/B)-3.35
Price to Sales (P/S)0.00
P/FCF Ratio-8.04
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$35.00Price Target Upside146.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.27
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Scalable Off-the-shelf ManufacturingA manufacturable, cryopreserved iNKT product that yields billions of cells per donor and requires no HLA matching materially reduces per-patient logistics and cost. This durable manufacturing capability supports rapid ICU deployment, broader addressable markets, and long-term commercial scalability.
Randomized Seamless Phase II/III ARDS TrialA prospectively randomized, seamless Phase II/III design aligned with FDA interactions creates a clear regulatory path and faster de-risking. Near-term readouts tied to survival and ventilator-free days can materially change program value and determine registrational strategy within a single protocol.
Encouraging Translational And Survival SignalsAn unusually long median OS in a refractory gastric cancer cohort, plus coherent translational data across indications, strengthens the underlying biology and platform validity. Such reproducible mechanistic signals support cross-indication development and long-term partnership and licensing interest.
Bears Say
Zero Revenue And Persistent Operating LossesAs a pre-commercial biotech with no product revenue and sustained multi-year losses, the company depends on external financing to fund R&D. Persistent deficits reduce resilience to setbacks and raise execution risk, potentially forcing program delays or dilution in adverse funding scenarios.
Weak Balance Sheet And Volatile Cash GenerationModest cash on hand, recurring negative operating/free cash flow, and negative equity in prior years constrain financial flexibility. This structural funding pressure increases likelihood of dilution or curtailed programs and limits the company's ability to finance multiple concurrent trials or scale commercialization.
Execution, Regulatory And ARDS Program RiskARDS is biologically heterogeneous and has seen inconsistent success with cell therapies; early investigator data require randomized confirmation. Regulatory, biomarker stratification and geopolitical trial execution risks can prolong timelines, enlarge required trials, and materially raise development costs.
MiNK Therapeutics News
INKT FAQ
What was MiNK Therapeutics’s price range in the past 12 months?
MiNK Therapeutics lowest stock price was $8.48 and its highest was $30.30 in the past 12 months.
What is MiNK Therapeutics’s market cap?
MiNK Therapeutics’s market cap is $53.85M.
When is MiNK Therapeutics’s upcoming earnings report date?
MiNK Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 26 days.
How were MiNK Therapeutics’s earnings last quarter?
MiNK Therapeutics released its earnings results on May 15, 2026. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is MiNK Therapeutics overvalued?
According to Wall Street analysts MiNK Therapeutics’s price is currently Undervalued.
Does MiNK Therapeutics pay dividends?
MiNK Therapeutics does not currently pay dividends.
What is MiNK Therapeutics’s EPS estimate?
MiNK Therapeutics’s EPS estimate is -0.6.
How many shares outstanding does MiNK Therapeutics have?
MiNK Therapeutics has 4,981,899 shares outstanding.
What happened to MiNK Therapeutics’s price movement after its last earnings report?
MiNK Therapeutics reported an EPS of -$0.57 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.998%.
Which hedge fund is a major shareholder of MiNK Therapeutics?
Currently, no hedge funds are holding shares in INKT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MiNK Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (146.31% Upside)
$35.00 (146.31% Upside)
Hedge Fund Trend
Decreased
By 3.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.86%
12-Months-Change
Fundamentals
Return on Equity
76.02%
Trailing 12-Months
Asset Growth
143.17%
Trailing 12-Months
Company Description
MiNK Therapeutics
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
INKT Stock 12 Month Forecast
Average Price Target
$35.00
▲(146.31% Upside)
Technical Analysis
Ownership Overview
4.80% Insiders
1.43% Mutual Funds
0.36% Other Institutional Investors
91.90% Public Companies and
Individual Investors